Schmid, Florian A.
Prange, Jenny A.
Kozomara, Marko
Betschart, Cornelia
Sousa, Rosa A.
Steinke, Nicolas
Hunziker, Manuela
Lehner, Fabienne
Veit, Markus
Grossmann, Regina
Landsmann, Anna
Hötker, Andreas M.
Boss, Andreas
Mohr-Haralampieva, Deana
Eberli, Daniel
Funding for this research was provided by:
H2020 European Institute of Innovation and Technology (731377)
University of Zurich
Article History
Received: 20 December 2022
Accepted: 18 February 2023
First Online: 12 April 2023
Declarations
:
: F.A.S., M.K., C.B., R.A.S., N.S., M.H., F.L., M.V., R.G., A.L., A.M.H., A.B.: none. The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: J.A.P., D.M.H. and D.E. own stocks in the company MUVON Therapeutics AG, aimed at further developing MPC therapy towards a commercial product. No company employees were involved in conducting the study or analysis of the presented study. Besides that, no other relation, benefit, potential conflict must be reported in the context of this study. All other authors declare that the research presented in this study was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.